Dyskeratosis congenita of Zinsser–Cole–Engman

Dyskeratosis Congenita of Zinsser–Cole–Engman is a rare, genetically inherited, multisystem disorder characterized by the triad of reticulated skin pigmentation, nail dystrophy, and mucosal leukoplakia. This condition is also associated with a predisposition to cancer and bone marrow failure. Dyskeratosis Congenita (DC) affects both males and females and can present in various forms, depending on the genetic mutation involved.

Etiology and Genetics

Dyskeratosis Congenita is primarily caused by mutations in genes that are involved in the maintenance of telomeres. Telomeres are protective caps at the ends of chromosomes that ensure chromosome stability. Mutations in at least 13 genes have been identified in association with DC, with the most common being mutations in the DKC1, TERC, TERT, and TCAB1 genes. These mutations lead to premature telomere shortening, which triggers a cascade of cellular dysfunctions.

Clinical Features

The hallmark features of Dyskeratosis Congenita include:

• Reticulated Skin Pigmentation: A lace-like pigmentation that typically appears in the first decade of life.
• Nail Dystrophy: Brittle, ridged, or absent nails.
• Oral Leukoplakia: White patches on the mucous membranes of the mouth.

Additional symptoms may include dental abnormalities, bone marrow failure, pulmonary fibrosis, liver disease, and an increased risk of developing cancers, particularly of the skin, head, neck, and gastrointestinal tract.

Diagnosis

Diagnosis of Dyskeratosis Congenita is based on clinical presentation and family history. Genetic testing can confirm the diagnosis by identifying mutations in the associated genes. Telomere length analysis in peripheral blood leukocytes is also a diagnostic tool, as individuals with DC typically have significantly shorter telomeres compared to age-matched controls.

Treatment

There is no cure for Dyskeratosis Congenita. Treatment focuses on managing symptoms and preventing complications. Androgens and growth factors may be used to treat bone marrow failure. Hematopoietic stem cell transplantation (HSCT) may be considered for patients with severe bone marrow failure, although this procedure carries significant risks. Regular monitoring for the development of malignancies and organ dysfunction is essential for managing the long-term health of individuals with DC.

Prognosis

The prognosis for individuals with Dyskeratosis Congenita varies widely and depends on the severity of bone marrow failure, the development of malignancies, and the success of treatments. Early diagnosis and intervention can improve the quality of life and life expectancy of individuals with DC.

Dyskeratosis congenita of Zinsser–Cole–Engman Resources
Latest articles Most recent articles Ongoing trials	Wikipedia